News Sentiment

LEGN sentiment intelligence

Legend Biotech Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 66 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 27.08 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-9.5% over one week, -24.5% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Lobbying Update: $90,000 of LEGEND BIOTECH CORPORATION lobbying was just disclosed

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -9.5% Price reacting lower
Trend fit Trend active -24.5% over four weeks
Fair value -35.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 48
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 10
TradingView 6
GuruFocus 5
simplywall.st 5
Quiver Quantitative 2
Investing.com Nigeria 2
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 16
Analyst action 8
Balance sheet 3
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 66
Quiver Quantitative Direct company coverage

Lobbying Update: $90,000 of LEGEND BIOTECH CORPORATION lobbying was just disclosed

LEGEND BIOTECH CORPORATION (LEGN) disclosed $90,000 in lobbying expenses for Q2 2026, focusing on educating Congress about biotechnology's role in healthcare. Insider trading data shows two sales by the CEO, totaling $169,404, while hedge funds exhibit mixed activity with signifi

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 23:13
Source
Quiver Quantitative
Stock Titan Direct company coverage

Legend Biotech (NASDAQ: LEGN) reports $657M CARVYKTI sales

Legend Biotech (NASDAQ: LEGN) reported preliminary net trade sales of approximately $657 million for CARVYKTI® for the quarter ended June 30, 2026, based on data provided by Janssen. This figure has not been independently verified or audited by Legend Biotech's accountants and is

Tone
Positive 61/100
Event
Earnings
Published
15 Jul 2026 11:13
Source
Stock Titan
Investing.com Nigeria Direct company coverage

JPMorgan resumes Legend Biotech stock coverage with neutral rating By Investing.com

JPMorgan has resumed coverage of Legend Biotech Corp. (NASDAQ: LEGN) with a Neutral rating and a price target of $35.00 for December 2027. The firm acknowledges the strong launch of Legend Biotech's Carvykti but expresses concerns about competitive threats and the unproven potent

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 12:10
Source
Investing.com Nigeria
GuruFocus Direct company coverage

LEGN Reinstated by JP Morgan -- Rating Set to Neutral

JP Morgan has reinstated Legend Biotech (LEGN) with a Neutral rating and a price target of $35.00, reflecting a cautious outlook despite the stock being significantly undervalued according to GuruFocus's GF Value™. While LEGN shows strong growth potential and momentum, its high f

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 11:41
Source
GuruFocus
GuruFocus Direct company coverage

JPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutral Outlook

JPMorgan has initiated coverage of Legend Biotech (LEGN) with a Neutral rating and a $35 price target, citing a strong launch for its CAR T-cell therapy Carvykti but expressing caution regarding competitive pressures. The company, with a market cap of $5.24 billion and a GF Score

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 10:41
Source
GuruFocus
MarketBeat Direct company coverage

Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026

As of June 30, 2026, Legend Biotech (LEGN) had a short interest of 13.11 million shares, representing 7.06% of the public float. This was a 0.96% increase from the previous report, with a short interest ratio of 4.2 days to cover. The article provides a detailed historical overvi

Tone
Negative 35/100
Event
Market update
Published
10 Jul 2026 07:10
Source
MarketBeat
www.marketscreener.com Direct company coverage

RBC Capital Adjusts Legend Biotech Price Target to $63 From $64, Maintains Outperform Rating

RBC Capital has revised its price target for Legend Biotech (NASDAQ: LEGN) to $63, down from $64, while reaffirming its "Outperform" rating on the stock. This adjustment comes amidst recent news regarding the company's financial activities and clinical trial data. Legend Biotech

Tone
Positive 59/100
Event
Analyst action
Published
07 Jul 2026 12:11
Source
www.marketscreener.com
Ad-hoc-news.de Direct company coverage

Legend Biotech Corp highlights cell therapy pipeline as shares trade on Nasdaq

Legend Biotech Corp is advancing its cell therapy pipeline, focusing on oncology and immunology treatments, as its shares trade on Nasdaq. The company specializes in autologous cell therapy platforms and is recognized for its investigational therapies in hematologic malignancies

Tone
Positive 66/100
Event
Regulatory and legal
Published
03 Jul 2026 22:13
Source
Ad-hoc-news.de
Stock Titan Direct company coverage

Legend Biotech (LEGN) CEO Ying Huang makes charitable gift of 3,382 shares

Legend Biotech Corp's CEO and director, Ying Huang, reported a charitable gift of 3,382 Ordinary Shares to a charitable organization. This transaction, filed as a Form 4, involved no cash consideration and leaves Huang with a direct ownership of 238,490 Ordinary Shares. The compa

Tone
Neutral 50/100
Event
Balance sheet
Published
03 Jul 2026 18:10
Source
Stock Titan
Stock Titan Direct company coverage

Legend Biotech (LEGN) director sells 6,000 shares at $14.80 each in open-market trade

Legend Biotech Corp director Casey Patrick John sold 6,000 Ordinary Shares in an open-market transaction at $14.80 per share, or $29.60 per American Depositary Share (ADS). After the sale, Mr. John directly holds 48,604 Ordinary Shares, indicating a continued significant equity s

Tone
Negative 29/100
Event
Market update
Published
03 Jul 2026 18:10
Source
Stock Titan
GuruFocus Direct company coverage

Insider Sell Alert: Patrick Casey Sells 6,000 Shares of Legend B

Patrick Casey, a Director at Legend Biotech Corp (LEGN), sold 6,000 shares of the company on June 30, 2026, reducing his holdings to 48,604 shares. This transaction follows a period of no insider buys and three insider sells over the past year for Legend Biotech. The stock is cur

Tone
Negative 31/100
Event
Market update
Published
02 Jul 2026 23:10
Source
GuruFocus
Finviz Direct company coverage

LEGN - Legend Biotech Corp ADR Earnings

This article provides detailed financial data and performance metrics for Legend Biotech Corp ADR (LEGN). It includes key financial figures like market cap, income, sales, EPS, and various ratios, alongside stock performance over different periods. The data also covers ownership

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 16:39
Source
Finviz
TradingView Direct company coverage

Legend Biotech Corporation Stock 12‑Month Price Target Cut to $55.21, Implies 85% Upside

Legend Biotech Corporation's average 12-month stock price target has been lowered from $56.13 to $55.21 by 14 analysts, with forecasts ranging from $27 to $86 per share. This new target implies an 85% potential upside based on the July 1 closing price. Despite the target cut, the

Tone
Positive 63/100
Event
Analyst action
Published
02 Jul 2026 16:10
Source
TradingView
Finviz Direct company coverage

LEGN - Legend Biotech Corp ADR Options

This page provides a detailed financial overview of Legend Biotech Corp (LEGN), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $29.91, showing a slight increase. The dat

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 15:40
Source
Finviz
Investing.com Nigeria Direct company coverage

Form 144 Legend Biotech Corp For: 30 June By Investing.com

This article reports on the filing of Form 144 by Legend Biotech Corp for the period ending June 30. It provides financial market data including indices, commodities, bonds, and shares, along with a list of trending stocks and recent market movers. The article is a brief announce

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 15:12
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Form 144 Proposed ADS Sale (NASDAQ: LEGN)

A Form 144 filing indicates a proposed sale of 3,000 American Depositary Shares (ADS) of Legend Biotech Corp (NASDAQ: LEGN) through Fidelity Brokerage Services LLC, valued at $88,800. The filing also details multiple past restricted stock vesting events totaling 3,000 ADS between

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 14:38
Source
Stock Titan
Investing.com South Africa Direct company coverage

Form 4 Legend Biotech Corp For: 29 June By Investing.com

This article announces the filing of Form 4 for Legend Biotech Corp for June 29, as reported by Investing.com. It is a brief administrative notice primarily serving to disseminate this financial filing information. The content primarily consists of market data, trending stocks, a

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 03:10
Source
Investing.com South Africa
Stock Titan Direct company coverage

Legend Biotech (NASDAQ: LEGN) CEO disposes shares to cover RSU tax

Legend Biotech Corp's CEO, Ying Huang, reported the disposition of 5,566 ordinary shares on June 25, 2026, at a weighted average price of $14.78 per share. This transaction was non-discretionary and solely to cover withholding tax obligations upon the vesting of restricted share

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 03:10
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Legend Biotech Corporation – NASDAQ:LEGN

This article displays the "Price to sales forward" metric for Legend Biotech Corporation (NASDAQ: LEGN) on TradingView. It provides market data and financial information for the company, accessible through the TradingView platform. The page shows that the market was closed at the

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

Legend Biotech Corp. Sponsored ADR Actuals & Estimates (NASDAQ:LEGN)

This page provides an overview of Legend Biotech Corporation's financial actuals and estimates, including reported data and analyst projections for income statements, balance sheets, cash flow, and valuation metrics. Users can compare actual results with average, high, and low es

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 01:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Legend Biotech Corporation – NASDAQ:LEGN

This article displays the "Enterprise value to EBIT forward" metric for Legend Biotech Corporation (NASDAQ: LEGN) on TradingView. It indicates that the market was closed with no trades at the time of the data capture. The content is primarily a screenshot or data display from the

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 22:11
Source
TradingView
Stock Titan Direct company coverage

LEGN (NASDAQ) notice: Director/entity proposes sale of 2,783 ADS

Legend Biotech Corp (LEGN) has filed a Form 144 proposing the sale of 2,783 American Depositary Shares (ADS) linked to a Restricted Stock Vesting event on June 22, 2026. The filing indicates a value of $79,016.88 and mentions execution through Fidelity Brokerage Services LLC. It

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 19:11
Source
Stock Titan
Kavout | AI Direct company coverage

What Did the Recent CARVYKTI Data Reveal About Its Potential

Legend Biotech's CARVYKTI demonstrates strong efficacy and safety for multiple myeloma, with recent data supporting its use earlier in treatment. The company reported a significant surge in Q1 2026 sales, driven by global expansion and improved manufacturing efficiency, positioni

Tone
Positive 92/100
Event
Market update
Published
26 Jun 2026 09:10
Source
Kavout | AI
TradingView Direct company coverage

Enterprise value to revenue forward of Legend Biotech Corporation – NASDAQ:LEGN

This article from TradingView is a placeholder or an incomplete page focusing on the "Enterprise value to revenue forward" metric for Legend Biotech Corporation (NASDAQ:LEGN). It displays basic company information and navigation links for financial data, news, and community secti

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 23:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Legend Biotech Corporation – NASDAQ:LEGN

The article provides financial data for Legend Biotech Corporation (NASDAQ: LEGN), specifically focusing on its Price to Book Forward metric. It displays the current value, change, and percentage change for this financial indicator. The content appears to be a snapshot from a fin

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 21:09
Source
TradingView
Market source Direct company coverage

Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress

UBS has raised its price target for Legend Biotech Corporation (LEGN) to $49, reiterating a Buy rating, due to promising early clinical findings for its LB5006 program. Additionally, the company reported positive initial clinical proof-of-concept results for LB2501, an investigat

Tone
Positive 72/100
Event
Analyst action
Published
25 Jun 2026 13:09
Source
Market source